Tag
The FIBRONEER-ILD trial demonstrates nerandomilast’s potential to slow lung function decline and reduce mortality in patients with autoimmune-related progressive pulmonary fibrosis, with a favorable safety profile.
An in-depth analysis of the FIBRONEER-IPF trial’s extended follow-up data, evaluating the efficacy and safety of the PDE4B inhibitor nerandomilast in reducing clinical events and mortality in patients with idiopathic pulmonary fibrosi
Long-term data from the FIBRONEER-IPF trial indicates that while nerandomilast did not significantly impact composite respiratory events, the 18 mg dose suggests a numerical reduction in mortality and maintains a favorable safety profile fo
This article analyzes the long-term follow-up data from the FIBRONEER-IPF trial, evaluating the efficacy of nerandomilast in idiopathic pulmonary fibrosis. While the drug reduces FVC decline, its impact on composite clinical outcomes remain
Phase 3 trials demonstrate that nerandomilast, a selective PDE4B inhibitor, significantly slows lung function decline in idiopathic and progressive pulmonary fibrosis over 52 weeks, with manageable safety profiles.
